Evidence map›Paper›PMID 35311466›Full record

ArticlePharmaceutical biology2022

Berberine alleviates myocardial ischemia-reperfusion injury by inhibiting inflammatory response and oxidative stress: the key function of miR-26b-5p-mediated PTGS2/MAPK signal transduction.

Xiaojing Jia, Wei Shao, Suqing Tian

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Frontiers in pharmacology · 2025
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Xiaojing JiaDepartment of Pharmacy, The First People's Hospital of Lianyungang, Lianyungang, China.
Wei ShaoDepartment of Pharmacy, Pingyi County Hospital of Traditional Chinese Medicine, Linyi, China.
Suqing TianDepartment of Pharmacy, Jining Hospital of Traditional Chinese Medicine, Jining, China.ORCID 0000-0001-7377-032X
Jining Traditional Chinese Medicine Hospital · CNLinyi City Chinese Medicine Hospital · CNThe First People’s Hospital of Lianyungang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextBerberine has myocardial protective effects.

objectivesThe protective effects of berberine on heart ischemia-reperfusion (I/R) injury were explored. MATERIALS AND

methodsHuman cardiomyocytes were divided into control group, oxygen-glucose deprivation/re-oxygen (OGD/R) (2 h OGD with 24 h reoxygenation) group, OGD/R + low group (5 μM berberine for 24 h) and OGD/R + high group (10 μM berberine for 24 h). Twenty-four Wistar rats were divided into sham group, I/R group (45 min occlusion with 2 h reperfusion), I/R + berberine group (50 mg/kg berberine 1 h before I/R surgery) and I/R + berberine + antagomir (intraperitoneally injected with miR-26b-5p antagomir). MicroRNA profile, effects of berberine on I/R or OGD/R-induced injuries, and the role of miR-26b-5p in the function of berberine were explored.

resultsOGD/R treatment suppressed viability (0.41 ± 0.05 vs. 0.87 ± 0.13, DISCUSSION AND

conclusionsBerberine exerted anti-I/R function in heart by inducing miR-26b-5p and suppressing the PTGS2/MAPK pathway. These data promote the application of berberine as an anti-I/R agent.

Indexed as

AnimalsApoptosisBerberineCells, CulturedCyclooxygenase 2HumansInflammationMaleMAP Kinase Signaling SystemMicroRNAsMyocardial Reperfusion InjuryOxidative StressRatsRats, WistarBerberineCyclooxygenase 2MicroRNAsMIRN26 microRNA, humanPTGS2 protein, humanCardiovascular diseaseinflammationmicroRNAnatural compound

Identifiers

PMID35311466
PMCPMC8967400
OpenAlexW4220999024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.